Reading a Certificate of Analysis

Overview

A Certificate of Analysis (COA) is a document issued by a manufacturer or third-party laboratory that reports the results of quality control testing performed on a specific batch of product. For research peptides, COAs provide critical information about identity, purity, and safety — data that allows researchers to assess whether a product meets the standards required for their work.

Reading a COA effectively requires understanding what each test measures, what acceptable values look like, and what limitations the document carries. A well-constructed COA provides confidence that the peptide is what it claims to be and is free from harmful contaminants. A poorly constructed or fraudulent COA, by contrast, can create a false sense of security. Knowing the difference is a practical skill for anyone working with research peptides.

This article explains the standard components of a peptide COA, how to interpret each section, and how to identify documentation that may be unreliable.

Background

Why COAs Matter

Research peptides purchased from non-pharmaceutical sources are not subject to the rigorous manufacturing oversight that applies to approved drugs. Without regulatory enforcement of quality standards, the COA serves as the primary quality assurance document. Studies analyzing commercially available research peptides have found that actual content can vary significantly from label claims — some products contain less peptide than stated, some contain the wrong peptide entirely, and some harbor bacterial endotoxins or other contaminants.

A legitimate COA from a reputable laboratory provides objective data to verify product quality. However, COAs can also be fabricated, reused across batches, or generated by unaccredited laboratories with questionable methods. The ability to critically evaluate a COA is therefore as important as the document itself.

Standard Testing Methods

Peptide quality control relies on a core set of analytical techniques, each providing different information:

• High-Performance Liquid Chromatography (HPLC): Measures purity by separating the target peptide from impurities based on their interactions with a chromatographic column
• Mass Spectrometry (MS): Confirms molecular identity by measuring the molecular weight of the peptide
• Amino Acid Analysis (AAA): Verifies the amino acid composition of the peptide
• Endotoxin Testing: Detects bacterial endotoxin contamination (Limulus Amebocyte Lysate or LAL test)
• Appearance/Solubility Testing: Basic physical characterization

Key Findings

Document Header and Batch Information

Every legitimate COA should include:

• Product name and catalog number: The peptide identity as sold by the supplier
• Batch or lot number: A unique identifier for the specific production batch. This is critical — a COA without a batch number cannot be verified against a specific product
• Sequence: The amino acid sequence of the peptide, typically in single-letter code (e.g., GQRETPEGAEAKPWY for BPC-157) or three-letter code. Verify this matches the expected sequence for the compound
• Molecular weight: The calculated molecular weight based on the sequence, and ideally the observed molecular weight from mass spectrometry
• Molecular formula: The chemical formula of the peptide
• Date of analysis: When the testing was performed. COAs dated far from the manufacture date, or with no date at all, are suspect
• Analyst/authorized signatory: The name or identifier of the person who conducted or approved the analysis

HPLC Purity Analysis

HPLC is the primary method for assessing peptide purity. The technique separates molecules in solution as they pass through a column packed with stationary phase material. Different molecules interact differently with the column, causing them to elute at different times. A detector (typically UV absorbance at 214-220 nm for peptides) records the signal as molecules exit the column, producing a chromatogram.

What to look for:

• Purity percentage: Reported as the area percentage of the main peak relative to all peaks in the chromatogram. Research-grade peptides typically have purities of 95% or higher. Values above 98% indicate high purity. Values below 90% suggest significant impurity content.

• Retention time: The time at which the peptide elutes from the column. While the absolute retention time varies with method and conditions, it should be consistent with the expected behavior of the peptide.

• Chromatogram inclusion: A credible COA includes the actual HPLC chromatogram — the graphical trace showing the peaks. This is far more informative than a purity number alone. Look for:

  • A single dominant peak (the target peptide) that is well-resolved from any impurity peaks
  • Minimal baseline noise or drift
  • Clearly labeled axes (time in minutes on x-axis, absorbance or intensity on y-axis)

• Method description: The COA should specify the HPLC method parameters — column type (typically C18 reversed-phase), mobile phase composition (acetonitrile/water gradients with TFA), flow rate, and detection wavelength. Without method information, the results cannot be independently replicated or evaluated.

Common impurities visible on HPLC:

• Deletion sequences: Peptides missing one or more amino acids from the target sequence, resulting from incomplete coupling reactions during synthesis. These appear as smaller peaks near the main peak.
• Truncated sequences: Shorter fragments resulting from premature chain termination
• Oxidized species: Peptides where methionine, tryptophan, or cysteine residues have been oxidized, often eluting as a shoulder on the main peak or a nearby separate peak
• TFA/acetate salts: Counterions from the purification process, which may not appear on HPLC but affect the net peptide content

Mass Spectrometry

Mass spectrometry (MS) confirms the molecular identity of the peptide by measuring its mass-to-charge ratio. The two most common ionization methods for peptides are electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI).

What to look for:

• Observed molecular weight vs. calculated molecular weight: These should agree within the instrument's mass accuracy — typically within 0.1 Da for high-resolution instruments or within 1-2 Da for lower-resolution instruments. A discrepancy suggests the product is not the expected peptide.

• Charge state distribution (ESI-MS): ESI typically produces multiply charged ions. A clean spectrum shows a series of peaks corresponding to different charge states ([M+2H]2+, [M+3H]3+, etc.) that all deconvolute to the same molecular weight.

• Mass spectrum inclusion: As with HPLC, the actual mass spectrum should be included in the COA. A well-resolved spectrum with a dominant signal at the expected mass provides strong confirmation of peptide identity.

Limitations of MS:

• MS confirms molecular weight but does not distinguish between sequence isomers — peptides with the same amino acid composition but different sequences will have identical masses
• MS alone does not quantify purity — a product could be confirmed by MS but still have low HPLC purity due to closely related impurities at different concentrations

Amino Acid Analysis (AAA)

AAA involves hydrolyzing the peptide into its constituent amino acids and quantifying each one. This confirms the amino acid composition matches the expected sequence.

What to look for:

• Observed ratios vs. theoretical ratios: Each amino acid should be present at a ratio consistent with the expected sequence. For example, a peptide with two glycine residues and one leucine residue should show a Gly:Leu ratio of approximately 2:1.
• Net peptide content: AAA can determine the actual peptide content of the powder by weight, accounting for salt content, moisture, and counterions. Research-grade peptides typically have net peptide content of 60-80% of the total powder weight, with the remainder being counterion salts (TFA or acetate) and residual moisture.

AAA is not always included in standard COAs but is particularly valuable because it provides an independent confirmation of identity and quantifies actual peptide content.

Endotoxin Testing

Bacterial endotoxins (lipopolysaccharides from gram-negative bacteria) are a critical safety concern for injectable products. The Limulus Amebocyte Lysate (LAL) test or recombinant Factor C (rFC) assay detects endotoxin contamination.

What to look for:

• Endotoxin level: Reported in Endotoxin Units per milligram (EU/mg). For research peptides intended for injection, levels should be below 5 EU/kg body weight (a standard derived from pharmaceutical requirements). Many suppliers report endotoxin levels below 0.5 EU/mg as a quality benchmark.
• Test method: LAL gel-clot, LAL turbidimetric/chromogenic, or rFC assay. The specific method should be stated.

Not all COAs include endotoxin testing. Its absence does not necessarily indicate a problem, but for peptides intended for any in vivo application, endotoxin data provides an important safety metric.

Appearance and Solubility

Basic physical characterization is typically reported:

• Appearance: Most lyophilized peptides appear as white to off-white powder. Significant discoloration (yellow, brown) may indicate degradation or impurities.
• Solubility: Some COAs report solubility in specified solvents (water, DMSO, dilute acetic acid). This is useful for reconstitution planning but does not directly reflect quality.

Current State

Red Flags in COA Documentation

Several indicators suggest a COA may be unreliable:

• No batch/lot number: Without this, the COA cannot be linked to a specific product
• No chromatogram or spectrum: A purity value without supporting graphical data cannot be independently evaluated
• Suspiciously perfect purity (>99.9%): While achievable, extremely high purity claims should be verified with corroborating data. A purity of exactly 99.0% or 99.5% across multiple different batches suggests the number may be fabricated
• Identical COAs across batches: Every batch should have unique analytical data. Reused chromatograms indicate copied documentation
• No method information: Without knowing how the analysis was performed, the results are unverifiable
• No date or analyst information: Suggests the document may not originate from a real analytical event
• Mismatched molecular weight: If the MS data does not match the expected molecular weight for the named peptide, the product identity is in question
• Template-style formatting: Generic COA templates with fields simply filled in (rather than instrument-generated reports) are easier to fabricate

Third-Party Testing

The gold standard for quality verification is independent third-party testing — sending a sample to an accredited analytical laboratory that has no financial relationship with the supplier. Organizations offering peptide testing services include university core facilities, contract research organizations, and independent analytical laboratories.

Third-party testing adds cost and time but provides the highest confidence in product quality, particularly for critical research applications. Some community-driven testing initiatives have emerged where users collectively fund independent analyses and share results publicly.

Future Directions

• Digital verification: Blockchain-based COA systems that create tamper-proof records linking batch numbers to analytical data, preventing document fabrication
• Standardized COA formats: Industry initiatives to establish minimum reporting requirements for research peptide COAs, including mandatory chromatogram and spectrum inclusion
• QR-code linked data: COAs linked to full analytical datasets (raw chromatograms, spectra) accessible via QR codes, enabling deeper evaluation beyond the summary document
• AI-assisted COA evaluation: Machine learning tools that automatically assess COA credibility by analyzing chromatogram quality, checking internal consistency, and flagging anomalies
• Accreditation frameworks: Development of voluntary accreditation programs for research peptide manufacturers, with standardized testing and purity requirements

Related Topics

• Purity and Testing — Comprehensive overview of analytical methods used in peptide quality control
• Peptide Safety and Side Effects — How product quality relates to safety outcomes
• Compounding Pharmacy Peptides — Quality standards in the compounding sector
• Peptide Regulation Worldwide — Regulatory frameworks that govern quality requirements
• Peptide Bioconjugation — Analytical challenges for modified peptides